Company intelligence / Profile preview

Furen Pharmaceutical Group

Ownership: Private
Employees: ~2916
Development stage: Other

Overview

Furen Pharmaceutical Group has several programs in late-stage (Phase 3) as well as earlier stages, with a recombinant human coagulation factor VIII-Fc fusion protein in Phase 3 for hemophilia A and other programs in Phase 1 and Phase 2 for indications such as iron-deficiency anemia, asthma, and advanced malignancies[2].

Therapeutic areas: HematologyOncologyDermatologyPulmonology
Modalities: Small moleculeAntibody fusion proteinRecombinant protein
Industry: Biotech

Partnerships

Hetero Drugs Ltd. (India) – joint R&D on cancer and HIV treatments

Beyond the preview

Go deeper on Furen Pharmaceutical Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Furen Pharmaceutical Group.